dx eplex blood culture id gram-positive panel Search Results


90
GenMark Diagnostics eplex blood culture identification gram-positive (bcid-gp) panel
Eplex Blood Culture Identification Gram Positive (Bcid Gp) Panel, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dx+eplex+blood+culture+id+gram-positive+panel/pmc09614915-1-2-1?v=GenMark+Diagnostics
Average 90 stars, based on 1 article reviews
eplex blood culture identification gram-positive (bcid-gp) panel - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
GenMark Diagnostics dx eplex blood culture identification (bcid) gram-negative (bcid-gn) panel
Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of <t>ePlex</t> <t>BCID</t> panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).
Dx Eplex Blood Culture Identification (Bcid) Gram Negative (Bcid Gn) Panel, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dx+eplex+blood+culture+id+gram-positive+panel/pmc08370220-142-2-1?v=GenMark+Diagnostics
Average 90 stars, based on 1 article reviews
dx eplex blood culture identification (bcid) gram-negative (bcid-gn) panel - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

doi: 10.1128/AAC.00441-21

Figure Lengend Snippet: Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).

Article Snippet: The GenMark Dx ePlex blood culture identification (BCID) (research use only) Gram-positive (BCID-GP) and Gram-negative (BCID-GN) panels were used for retained blood samples that were frozen at −80°C.

Techniques: Comparison

Comparison of RDT platforms

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

doi: 10.1128/AAC.00441-21

Figure Lengend Snippet: Comparison of RDT platforms

Article Snippet: The GenMark Dx ePlex blood culture identification (BCID) (research use only) Gram-positive (BCID-GP) and Gram-negative (BCID-GN) panels were used for retained blood samples that were frozen at −80°C.

Techniques: Comparison, Bacteria